The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed implementation of guselkumab for the treatment of Crohn’s disease in line with NICE TA1095 AND Ulcerative Colitis in line with NICE TA1094.
Guselkumab for this indication will be considered as RED on the Joint Formulary with treatment initiation and continued prescribing by specialists in gastroenterology.
Where guselkumab is considered the most appropriate treatment option, the use of subcutaneous injection for initiation is more cost-effective than using iv infusion and would therefore be the preferred option.
Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD.
This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.
